Bach Group

The PPI targets we focus on are involved in redox signalling, oxidative stress, and inflammation, making them potential drug targets for various diseases, such as metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease (CKD), neurodegenerative disorders, and cancers.

Our main target is Keap1, which regulates Nrf2 and thereby endogenous antioxidant and anti-inflammatory responses. Additionally, we have developed inhibitors of the superoxide-generating multi-subunit enzyme complex NADPH oxidase 2 (NOX2), and recently, we expanded our focus to include tumor necrosis factor (TNF) receptors, their downstream PPIs, and protein phosphatases.

These PPIs are challenging to target with small molecules due to their relatively large, shallow, and polar interfaces. Current inhibitors often lack affinity, cellular potency, or drug-like properties. Additionally, the proteins are involved in complex networks of intracellular interactions. Therefore, more precise and effective molecules are needed as research tools to better understand the roles of these PPIs and to exploit them as drug targets for severe diseases.

1. Inhibiting the Keap1-Nrf2 PPI leads to Nrf2 activation and expression of antioxidant and anti-inflammatory proteins, thus Keap1 is a promising drug target for diseases involving oxidative stress and inflammation. Recent medicinal chemistry efforts from both academic and industrial laboratories have led to a rise in noncovalent Keap1-Nrf2 inhibitors. In our Drug Discovery Today review (Barreca and Qin et al, 2023), we provide a comprehensive overview of current noncovalent Keap1-Nrf2 inhibitors with a focus on their pharmacological effects, to examine the therapeutic potential of this promising potential future drug class. We also discuss the differences in pharmacodynamic effects and off-target profiles of covalent vs noncovalent small molecules that target Keap1 and activate Nrf2.

    Further description of our original contributions to the field of Keap1 drug discovery and other targets are seen below:

2. For Keap1, we analysed known inhibitors for their ability to cross the blood-brain barrier (Pallesen et al, 2018, J Med Chem). This was followed by a comparative assessment study, where the compounds from literature were tested in a range of assays to validate and compare their activity towards Keap1. Interestingly, about half of the reported Keap1 inhibitors were found to be false positives (Tran and Pallesen et al, 2019, J Med Chem and Derek Lowe’s blog).

3. We have addressed Keap1 by FBDD pursuing three strategies: First, we deconstructed the known compounds into a target-biased library of 77 fragments and tested them for Keap1 binding using four orthogonal biophysical assays. The binding modes of key fragment hits where determined by X-ray crystallography, which allowed us to merge two fragments into novel compounds with high affinities to Keap1 (Pallesen et al, 2021, J Med Chem; see also Practical Fragments blog).
   
   Secondly, we screened our commercial library of 2,500 fragments using four orthogonal methods. X-ray crystallography and fragment-to-lead (F2L) optimization resulted in novel fluorenone-based Keap1-Nrf2 inhibitors with a 1700-fold affinity-increase relative to the fragment hit (Narayanan and Tran et al, 2022, J Med Chem; and MAX IV’s news article).
   

   We then applied a conformational restriction strategy guided by X-ray crystallography, which led to new tetrahydroisoquinoline (THIQ) Keap1-Nrf2 inhibitors with significantly enhanced binding affinity and improved membrane permeability. Further optimization increased metabolic stability and cellular activity, and the compounds showed selectivity across a panel of homologues proteins (Qin et al, 2024, J Med Chem).

   
   Thirdly, we have screened the Diamond Light Source’s XChem library by X-ray crystallography. F2L optimization resulted in low nanomolar affinities and cellular potent, selective, anti-inflammatory drug-like molecules. RNA sequencing revealed activation of cytoprotective pathways and a different profile from typical covalent Nrf2 activators (Lin et al, 2025, Angew. Chem. Ind. Ed.; see also Practical Fragments blog). The compounds have been patented and we are currently wrapping-up the lead optimization focusing on pharmacokinetic/pharmacodynamic properties and obtaining in vivo proof-of-concept data in models of kidney and liver diseases. We are open to partnerships and pursuing commercial opportunities.”
   
   

4. We have used FBDD to develop novel inhibitors of the p47phox subunit of NOX2. We screened our 2,500 fragments by fluorescence polarization (FP) and thermal shift assay (TSA) followed by surface plasmon resonance (SPR) validation. Biostructural studies by NMR and SAXS indicated that two fragments bound to two separate binding sites in the elongated conformation of p47phox, and the design of bivalent inhibitors thereby resulted in a 20-fold enhancement in affinity (Solbak et al, 2020, J Med Chem).

   

   The bivalent inhibitors were then further optimized into a novel series of potent (submicromolar) NOX2 inhibitors, which were thoroughly characterized for binding to p47phox using biophysical methods and cellular activities in different cell lines. With this, we showed that p47phox can be targeted by potent small molecules, which may inspire future development of chemical probes and drug leads (Zang et al, 2023, J Med Chem). We have also assessed a literature compound suggested to target p47phox and inhibit NOX2. We found that the compound, LMH001, degraded within minutes in buffer and did not inhibit the p47phox/p22phox interaction, as suspected (Zang et al, 2023, Front Pharmacol).
   
   

5. PDZ domains are intriguing but challenging drug targets. We have investigated the druggability of PSD-95’s PDZ1-2 domain by fragment-based screening and a computational method. This resulted in new fragments shown to bind the PDZ domains of PSD-95 (Zang et al, 2020, ChemMedChem).
   

   

6. TNF receptors bind TNF cytokines and regulate inflammatory, immune, cell-survival, and cell-death signaling pathways (Chédotal et al, 2023, Drug Discov Today). In collaboration with Prof. Mads H. Clausen (Technical University of Denmark), we describe the discovery of new molecules for the extracellular domain of TNFR1 using fragment-based screening by NMR spectroscopy, followed by orthogonal validation by SPR and X-ray crystallography. F2L optimization included synthesis of 46 analogs and gave ∼10-fold improved affinity, although still in the low micromolar affinity area due to lack of deep pockets in TNFR1 that could adapt bigger and high-affinity molecules (Chédotal and Povlsen et al, 2026, ChemMedChem).
   
   
7. We have contributed to other collaboration projects: We used SPR to characterize protein-protein interactions related to KDM5B (Dorosz et al, 2019, Sci Rep), NEMO (Jussupow et al, 2020, Sci Adv), and CaMKIIa (Leurs et al, 2021, PNAS USA). We contributed with LC-MS pharmacokinetic data to a small-molecule obesity study (Grunddal et al, 2021, Mol Metab); and, we designed and synthesized novel Cas9 inhibitors by using a fragment-inspired deconstruction-reconstruction optimization strategy of a screening hit (Lee and Tran et al, 2022, J Med Chem).

We screen our libraries of fragments (small substructures <300 Da of drug-like molecules) by biophysical methods (FP, TSA, and SPR). Promising hits are optimized into lead compounds by medicinal chemistry, structure-based drug design guided by X-ray crystallography, and pharmacological assays for activity/affinity and DMPK properties.

Medicinal chemistry, biophysical methods (see SelectScience interview  about our SPR system), and X-ray crystallography are core techniques of our group. Cell assays and disease models are performed in collaboration with research groups in Denmark (University of Copenhagen, University of Southern Denmark, Aarhus University) and abroad.

We thank the following foundations for their generous support of our research: 

⦁ BioInnovation Institute (BII)

⦁ Novo Nordisk Foundation (Project Grants, Large Equipment and Facilities, Pioneer Innovator, SPARK Denmark)

⦁ UCPH Lighthouse

⦁ Independent Research Fund Denmark

⦁ Innovation Fund Denmark

⦁ The Carlsberg Foundation

⦁ Lundbeck Foundation (Fellowship and Ascending investigator)

⦁ MSC-ITN (UBIMOTIF)

⦁ China Scholarship Council

⦁ HALOS Cross Border Research Grant

⦁ Torben and Alice Frimodt´s Foundation

⦁ Simon Spies Foundation

⦁ Hørslev Foundation

If you are you interested in doing a master thesis project in the group, please send your CV, grades and motivations to anders.bach@sund.ku.dk for further discussions. We have projects both within chemistry and biological areas of drug discovery.

- Example of a Master Thesis Project:

Fragment-based drug discovery on protein-protein interactions (pdf)

Currently we have no open PhD and postdoc positions in our group. All vacancies are posted on the University’s job portal,